BofA raised the firm’s price target on Teva (TEVA) to $24 from $22 and keeps a Buy rating on the shares. Based on Q3 pricing and volume trends for key drugs as well as relevant company commentary, the firm previewed Q3 EPS updates for its commercial-stage biopharma coverage, telling investors that it does not expect any major Q3 beats/misses and no big 2026 revisions among the group.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva price target raised to $26 from $23 at JPMorgan
- Teva put volume heavy and directionally bearish
- Teva Pharmaceutical: Strategic Focus and Financial Stability Drive Buy Rating
- Teva price target raised to $26 from $23 at UBS
- Teva announces presentation of data from survey of patients taking AUSTEDO XR